The NIH director, Jay Bhattacharya, attributed the cancellation of $500 million in mRNA vaccine contracts to public distrust, claiming the platform's viability is compromised by low booster uptake. This contradicts Health Secretary Robert Kennedy Jr.'s explanation of ineffectiveness and safety concerns. Experts like Michael Osterholm criticized Bhattacharya's statement as disingenuous, highlighting the mRNA vaccines' proven safety and effectiveness, saving millions of lives. While acknowledging challenges in quantifying antigen production, they emphasize the need for continued research and improvement of the mRNA platform, rather than its abandonment.

Prepared by Olivia Bennett and reviewed by editorial team.